Yongchang Zhang, MD
Hunan Cancer Hospital
27
27
9
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+15 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
You Lu, MD
West China Hospital
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
yuankai shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (27)
Showing 20 of 27 trials
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma
A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma
Efficacy of Osimertinib in Patients With Lung Cancer
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer